In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Jun 22, 2016

Keywords

ClinConnect Summary

This clinical trial is studying a new way to deliver chemotherapy directly into the lungs during surgery for patients with sarcoma that has spread to the lungs. The goal is to target any tiny cancer cells that might still be present, which are often missed during surgery. This method, called In Vivo Lung Perfusion (IVLP), could potentially reduce the side effects of chemotherapy on other parts of the body while effectively treating the lung cancer.

To participate in this trial, patients must be under 65 years old, have a specific type of sarcoma with multiple lung lesions, and be in good overall health. They will undergo surgery where one lung will receive the new treatment while the other lung is treated with standard methods, like surgery or radiation. After the surgery, patients will be monitored for up to two years to check for safety and effectiveness. It's important to note that participants cannot have certain health conditions or previous treatments that might interfere with the study. This trial is currently recruiting participants, and it's an exciting opportunity to test a potentially better treatment for lung metastases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of Soft Tissue or Osteogenic Sarcoma
• • Presence of bilateral pulmonary metastases
• • 3 or more lung lesions in total
• • Age less than 65 years
• • ECOG 0-2
• • Absence of extra-pulmonary disease
• • Contralateral disease amenable to surgery or radiation
• • All lung lesions in the lung to be treated with IVLP can be resected with wedge or segmental resections (non-IVLP treated lung will be treated with radiation or surgery 4-12 weeks prior to IVLP)
• Exclusion Criteria:
• • Patient has previously received more than 450 mg of doxorubicin
• • Left Ventricular Ejection Fraction \<50%
• • History of significant pulmonary disease or pneumonitis
• • Pregnant or lactating females
• • Age 65 years or older, or less than 18 years
• • Inability to understand the informed consent process
• • Hypersenstivity to doxorubicin
• • Current participation in another therapeutic clinical trial
• • Previous lung metastatectomy